Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
about
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraineInfluence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprololLow migraine headache recurrence with naratriptan: clinical parameters related to recurrenceRizatriptan in acute treatment of migraine: update on new comparative data.How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.Cardiovascular tolerability and safety of triptans: a review of clinical data.Naratriptan: an alternative for migraine.Migraine: a comprehensive review of new treatment options.Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan.Safety and tolerability of rizatriptan.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of lifeNew paradigms in the recognition and acute treatment of migraine.Headache recurrence as a criterion for assessing efficacy of triptans: a perspective.Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability.A review of mechanisms of response to pain therapy: why voodoo works.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine.Triptans and chest symptoms: the role of pulmonary vasoconstriction.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.Rizatriptan in migraine.Treatment-emergent CNS symptoms following triptan therapy are part of the attack.Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.Comparative tolerability of treatments for acute migraine: A network meta-analysis.Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database.Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials.Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks.Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials.Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study.Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine.Differentiating the efficacy of 5-HT(1B/1D) agonists.Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials.
P2860
Q24801845-962E48F3-6502-4D0A-8A93-84C0C1B86D0CQ28343860-95861A15-EDC4-4750-B02F-6C963286AE6AQ28376494-142EC502-55F0-4D8F-BE85-329C7AE0501FQ30619774-6F5AF06C-98A8-43F5-AFFB-70DD8D56EC32Q30692301-6ED5EF2F-E997-4CD0-B551-83E923B34F3FQ30831647-DEF90FDE-B48C-4209-94A1-65D8FA3BEE6EQ30932202-5C3BE417-3298-4E43-AB11-03E5B9E907CBQ33689204-A3D8C201-DCC8-4066-AAE5-B79D71CEC255Q33715929-369098F6-EACF-4553-9FBA-F247E8BCE449Q33987376-23071AFD-16CE-4A3C-ACE7-777074E7F1BEQ34082303-3DC6593E-BE3F-4BCE-B399-7777901BB153Q34154647-ED17089B-1085-41CA-BB15-F21D7E338140Q34614148-C9C828AC-133B-44AE-8BDD-1465CDE8C72DQ34634345-F531E1AD-A232-480E-98E8-008D36CD2307Q34634351-C65DD11C-A27E-46D3-BCAE-6CF5C11B9166Q34691359-4044F6E2-092A-4F22-B3C7-880CABC91AB3Q35025912-9CCA1E61-7AEC-4D9E-8AA0-C4D263548631Q35091964-A5087AFE-DF34-4674-B904-531341F5535BQ35688196-B7298F67-BCF2-438F-98E8-F11F5D12892DQ35696691-31BA8EB5-3CC3-4193-88D6-624F66D3A442Q35775292-0E5A4DBB-E1CF-4F0E-A290-098A62E297B3Q36013751-6E7CE160-C536-4DC2-8093-21A47B67CBF8Q36257191-E2A14838-4A59-4669-8D4E-D210C9D862F7Q36768331-14290595-8F74-4D62-99E6-448AEC27E9C7Q37177502-ADCDE18E-5F78-4A63-81C0-35BDA5DF7F47Q38927015-9DCA1385-5457-4307-A8E7-FB15B28B5DB6Q39277602-3325C1F8-B6F6-4A5E-A2D1-783F6DDD2B8AQ39307655-11CD974E-73BF-4A17-928D-A5E5A893BF39Q39375725-E78DD918-0951-48EF-9816-3FB08ACC3765Q39402034-AB024B2B-B961-4A6E-B906-CF7DE07CDED7Q39407197-1CA8D363-0145-401F-BF8A-BB4E1CB8EAFAQ39407492-9BF7A883-3FA7-4CFC-AA35-DB2C52954D51Q39413834-A8CB01FC-4A45-4659-8EE4-B0BCA5C5BBC3Q39417517-225EB3E5-6535-4095-9B3C-99A2C3F77138Q39425621-BEDCFFE2-9A25-4507-8EC5-6C345859EBF7Q39437820-44E3A014-E398-4FA4-9D7A-B9915B4CE53CQ40356289-9709172B-4819-4171-BB9D-69F9C31B2B55Q42637517-C475D9BA-BB36-4CD6-865A-8D09B3DE5B75Q43551356-6D19E260-EAC0-4698-BD7A-5A5CB836F70FQ43989440-DF12D640-120D-4720-B960-0DF05876C1F7
P2860
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@en
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@nl
type
label
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@en
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@nl
prefLabel
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@en
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@nl
P2093
P1433
P1476
Rizatriptan (MAXALT) for the a ...... . Rizatriptan 022 Study Group.
@en
P2093
Willoughby E
P304
P356
10.1046/J.1526-4610.1998.3804281.X
P577
1998-04-01T00:00:00Z